Quality of life in patients with ovarian cancer treated with neoadjuvant AP chemotherapy depending on chemotherapeutic regimen

Assessing the results of antitumor therapy the quality of life (QOL) becomes a more important criterion than disease-free survival. The overall study objective was to assess the QOL in patients with ovarian cancer (OC) treated with AP chemotherapy depending on chemotherapeutic regimen. Materials and Methods. A total of 126 primary patients with OC (FIGO stage III-IV) were examined. All the patients were divided into 2 groups: 1st group underwent neoadjuvant autohemochemotherapy (NAHCT), 2nd group received neoadjuvant chemotherapy (NCT) according to a traditional AP regimen (cisplatin 75 mg/m2 and doxorubicin 50 mg/m2, intravenous fluid drip, 2 regimens spaced 21 days apart). Assessment of patients’ QOL was carried out using questionnaires EORTC-QLQ-C30 before chemotherapy, upon completion and 21 days after the procedure. Results. Before treatment the general status of patients in both groups was nearly the same. After two regimens of chemotherapy, the QOL, as well as general physical state and cognitive function decreased by 8 % in patients treated with NAHCT and by 14 % in those who received NCT. The general health status of all the patients didn’t differ much before the treatment. It decreased after 2 regimens of chemotherapy and 21 days after the undergone treatment the QOL increased by 24.2 % in the 1st group and by 7.2 % in the 2nd group. Conclusion. Using neoadjuvant AP chemotherapy in patients with OC decreases the patients’ QOL less, than NCT regimen. Moreover, it allows us to increase the overall QOL 21 days after the therapy.